MediQuest Therapeutics

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, MediQuest Therapeutics sits in the upper quartile of US sponsors by registered trial count (#1,604 of 15,742 sponsors by registered trial count).

8 total trials none currently recruiting 8 completed early-phase tilt upper quartile by trial count

MediQuest Therapeutics: 8 sponsored US clinical trials, none currently recruiting.

MediQuest Therapeutics sponsors 8 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 8 completed. 2 of these trials are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Raynaud Secondary to Other Autoimmune Disease, with 1 trials.

Upper-quartile sponsor footprint

MediQuest Therapeutics sits in the upper quartile of the sponsor corpus (#1,604 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Indexed trials (enrollment closed)

8 total, page 1 of 1

COMPLETED Phase 1

MQX-503 Applied to the Hand Versus Nitroglycerin Ointment Applied to the Chest: A Pharmacokinetic Comparison

NCT00841594
COMPLETED Phase 1

MQX-503 vs Nitroglycerin Ointment: A Pharmacokinetic Comparison in Normal Subjects

NCT00513994
COMPLETED Phase 2

Dose Response Study of a Topical Formulation of Nitroglycerin for the Treatment of Raynaud's Phenomenon

NCT00480753
COMPLETED Phase 3

Phase III Study of a Topical Gel Formulation for Treatment and Prevention of Raynaud's Phenomenon

NCT00419419
COMPLETED Phase 2

Dose Response Study of a Topical Gel for the Treatment of Raynaud's Phenomenon

NCT00378521
COMPLETED Phase 3

Phase III Study of Topical Gel for Treatment and Prevention of Raynaud's Phenomenon

NCT00266669
COMPLETED Phase 2

Topical Gel Anti-Fungal Agent for Tinea Unguium

NCT00253305
COMPLETED Phase 2

Lab Study of MQX-503 in Treatment of Raynaud's

NCT00253331

Phase Distribution

PhaseTrial count
Phase 1 2
Phase 2 4
Phase 3 2

Therapeutic Areas

Raynaud Secondary to Other Autoimmune Disease 1
Raynaud Disease Secondary to Scleroderma 1
Raynaud Disease 1
Raynaud's Disease 1
Scleroderma 1
Autoimmune Diseases 1

How the MediQuest Therapeutics early-phase archive is shaped

8 indexed studies, none listed as recruiting (0% open); 8 completed (100%).

Phase mix: 2 late (III/IV) vs 6 early (I/II) (early-phase heavy).

Top condition: Raynaud Secondary to Other Autoimmune Disease (1 trial), 5 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

MediQuest Therapeutics: archived-pipeline peers nationwide

Peers matched on 8 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

MediQuest Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%10%20%30%40% Total trials Recruiting share MediQuest TherapeuticsAB ScienceAbbott Point of CareAbeona TherapeuticsAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)10xBio22nd Century Group23andMe3-C Institute for Social Development
MediQuest Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

MediQuest Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 8 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this MediQuest Therapeutics page

8 registered trials is a research-attention snapshot, not an endorsement of MediQuest Therapeutics or any single study.

  • None of MediQuest Therapeutics's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Raynaud Secondary to Other Autoimmune Disease is the condition MediQuest Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Raynaud Secondary to Other Autoimmune Disease trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

MediQuest Therapeutics pipeline card: 8 registered trials from official public datasets.Report a data error.